System has raised $20 million in funding as it seeks to become a best-in-class provider of clinician-led peptide protocols by controlling more of its supply chain, prioritizing quality and transparency and bringing a sophisticated experience to a category that has largely lacked one.
The round was led by consumer-focused venture capital firm Patron Fund, with participation from Will Ventures, Vine, Courtside, Daybreak, SV Angel and RiverPark Ventures. System is part of a cohort of modern, VC-backed startups attracting capital as peptides move beyond their biohacking roots and toward mainstream wellness. They include Feel Peptides, which launched earlier this year with $3 million in funding, $6 million-backed Protocole and Superpower, which has raised $42 million.
Patron Fund partner Amber Atherton has been studying the peptide field since late 2024 in search of investment opportunities, encountering plenty of clandestine companies along the way selling questionable peptides on TikTok and elsewhere online. She views these dubious operators as a net negative for the industry and consumers. She gravitated to System in large part because founder and CEO Adam Steinle is the kind of leader she believes the category needs.
Before founding System, Steinle spent four years as a product manager at Meta and co-founded Y Combinator-backed Verse Therapy, an artificial intelligence-enabled pediatric therapy company that reached more than 100 clinics before being acquired in 2025. Discussing the creation of System, he says, “I didn’t think that any traditional healthcare brand was built correctly for this moment.”
Atherton describes Steinle as having both taste and ethics. She says, “Getting hundreds of millions of people to use a new type of supplement category requires deep consumer brand expertise.”
The commercial landscape for injectable wellness peptides has been polarized, especially since the United States Food and Drug Administration restricted traditional compounding pharmacies from preparing several popular peptides in 2023, a move Robert F. Kennedy Jr. is working to reverse. In July, an FDA advisory committee recommended adding six peptide families to the list of bulk drug substances that traditional compounding pharmacies can use under certain conditions. At the other end of the market from sketchy online sellers are ultra-premium concierge clinics that can cost thousands of dollars a month.
System is carving out a middle path. Positioned as a remote concierge medicine clinic “in your pocket” at a much lower, cash-pay price tag, the platform has amassed tens of thousands of patients subscribing to peptide protocols overseen by licensed clinicians. Treatments range from $89 to $219 a month, according to its website. Its current hero compounds include sermorelin and glutathione, and they’re paired with ongoing, asynchronous clinical access via text and Zoom.
System pays as much attention to aesthetics as it does access, adopting an elevated, luxury-minded clinical design that wouldn’t look out of place in the prestige beauty category. That elevated aesthetic has caught the eye of the fashion elite, with The Chérie recently dubbing System the ‘Loewe of telehealth.’”
System’s round comes as the peptide landscape is being supercharged by the mainstreaming of GLP-1 medications. Some 11% of American adults now report using GLP-1s for weight loss, according to Gallup, up from just 3% in 2024. Beyond increasing consumer awareness of peptides, their ubiquity has helped normalize self-injection, previously something anathema, or at least unsavory, to many wellness consumers.
“We have the uptake of GLP-1s where everybody knows people that are injecting themselves,” says Steinle. “The first time that you do this injection, you realize this is not a big deal at all.” For some System patients, subcutaneous shots have even become morning rituals, according to Steinle. He likens them to a more intense version of having a coffee or mixing a daily greens powder.
“I didn’t think that any traditional healthcare brand was built correctly for this moment.”
Geographically, System’s largest share of patients is in the American South, and its core patients are women aged 45 to 65. The company categorizes its user base into two distinct segments: “red growth moms” living in fast-growing cities like Scottsdale, reminiscent of the aesthetic popularized by “The Secret Lives of Mormon Wives,” and “whistle blue” creative tastemakers based in coastal cities like Los Angeles and New York.
To distinguish itself from telehealth players that rely on outside pharmacies to fill prescriptions, System has a compounding pharmacy in its network and is constructing a 14,000-square-foot U.S. compounding facility, with an active pharmaceutical ingredient manufacturer next on its roadmap. The strategy gives System tighter control over the sourcing, quality and production of its peptides and creates a transparent, made-in-America supply chain. The company states every product is third-party lab-tested.
Steinle says, “We would love to get to that state where we are known as the people who make quality peptides.”
The vertical integration also opens up a business-to-business opportunity. System plans to serve hormone clinics and independent doctors who want to prescribe high-quality, clinical-grade peptides through white label production.
System sees its sizable patient volume as another competitive advantage. Through regular blood tests and biomarker measurements, the company is compiling anonymized real-world data that it can use to understand how patients respond to different peptide protocols and make increasingly personalized recommendations. Steinle suggests the data can eventually create a substantial body of evidence around the safety and outcomes of peptide use outside of the sort of large, expensive clinical trials typically undertaken by pharmaceutical companies.
